Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.41 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.41 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.41 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.41 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248242 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL19121574 | 0.89 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL19121648 | 0.89 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL2758299 | 0.85 | ALDH1A1 (0.45) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL16951124 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL309306 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL2737289 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP2D6 | |
| SCHEMBL16950357 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL19122232 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 | |
| SCHEMBL8340815 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP1A1CYP1B1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| EP-2914256-A1 | DISUBSTITUTED AMINO ACIDS AND METHODS OF PREPARATION AND USE THEREOF | Aileron Therapeutics, Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| WO-2014071241-A1 | DISUBSTITUTED AMINO ACIDS AND METHODS OF PREPARATION AND USE THEREOF | AILERON THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | claimed |
| US-7244411-B2 | Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2007-07-17 | — | — | US | claimed |
| US-20070128729-A1 | Method for the identification and relative quantification of proteins based on the selective isolation of RRnK peptides for the simplification of complex mixtures of proteins | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2007-06-07 | — | — | US | claimed |
| EP-1785729-A2 | A method for the selective isolation of multiply-charged peptides applicable in the quantitative proteomics | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIGB) (CU) | 2007-05-16 | — | — | EP | claimed |
| EP-1589341-A2 | Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CIGB) (CU) | 2005-10-26 | — | — | EP | claimed |
| US-20050176085-A1 | Method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixtures | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2005-08-11 | — | — | US | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| US-5200526-A | Syntheses of optically pure α-amino acids from 3-amino-2-oxetanone salts | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1993-04-06 | — | — | US | claimed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2025078811-A1 | CANNABINOID COMPOUNDS AND USES THEREOF | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-12024580-B2 | Resin composition suitable for printing and printing methods | Montanuniversität Leoben (AT) | 2024-07-02 | — | — | US | disclosed |
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-06-25 | — | — | US | disclosed |
| WO-1990000551-A1 | PROCESS FOR THE PREPARATION OF QUINOLINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350950-A1 | Process for the preparation of quinoline antibacterial compounds | ABBOTT LABORATORIES (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4719289-A | ANTIGENS, IMMUNOADSORPTION, GLYCOLIPIDS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0175290-A2 | Glycopeptides, method for their preparation and their use | BEHRINGWERKE Aktiengesellschaft (DE) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018045-B2 | 17-beta-hydroxywithanolides and use thereof in treating cancer | HSD17B7, CYP17A1, HSD17B11 | ALDH1A1 67/4885CYP1A1 213/4885CYP1B1 273/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | ALDH1A1 789/4885CYP1A1 2100/4885CYP1B1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.